VivoSeq
Oncology

Advanced Hepatocellular Carcinoma

11

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Advanced Hepatocellular Carcinoma is an emerging landscape with 11 programs across 6 companies. The most active players are Sanofi, Eisai, Merck & Co.. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Roche logo

Roche

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

64%

Monoclonal antibody

7 of 11 classified programs — the dominant modality here.

36%ALL OTHERSSmall molecule436%

Monoclonal antibody leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Recruiting2 · 40%
Suspended1 · 20%

Clinical Trials

Trial Activity

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination With Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT04740307·116 enrolled
A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
Completed·NNational Taiwan University Hospital·Phase 2·NCT04294498·30 enrolled
A Phase Ib/II Study of Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Hepatocellular Carcinoma
Recruiting·NNorthwestern University·Preclinical·NCT07042919·59 enrolled
Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)
Recruiting·NRG Oncology·Phase 3·NCT07166406·226 enrolled
A Phase I Clinical Trial Investigating Autologous CAR T Cells Targeting GPC3 in Relapsed or Refractory Hepatocellular Carcinoma
Suspended·RRoswell Park Cancer Institute·Phase 1·NCT06968195·24 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)